OpGen, QIAGEN partner to advance rapid diagnostics for antimicrobial resistant bacteria
OpGen has partnered with QIAGEN to advance rapid diagnostics for antimicrobial resistance (AMR).
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
01 Nov 18
OpGen has partnered with QIAGEN to advance rapid diagnostics for antimicrobial resistance (AMR).
31 Oct 18
CellProThera and BioCardia have partnered for clinical trial and marketing in Singapore of early stem cell therapy for…
31 Oct 18
Point-of-care (POC) tests developer RPS Diagnostics has received updated CE Mark for its FebriDx test to allow incorporation…
31 Oct 18
Illumina has launched TruSight Oncology 500 (TSO 500) pan-cancer assay to power comprehensive, accurate, pan-cancer tumor profiling.
26 Oct 18
Candesant Biomedical has announced positive initial safety and efficacy data from its STAYDRi.1 trial on CDX-101, a new…
25 Oct 18
Debiopharm Group member GenePOC has secured approval from Health Canada and launched its GenePOC CDiff assay for use…
25 Oct 18
TP Therapeutics and Almac Diagnostic Services have signed a collaboration agreement for the development and commercialization of a…
24 Oct 18
Cancer-focused genetic testing services provider NeoGenomics has agreed to acquire clinical oncology laboratory, Genoptix, for $125m in cash.
23 Oct 18
Siemens Healthineers is set to invest RMB3bn ($433m) to construct a new laboratory diagnostics plant in Shanghai, China.
17 Oct 18
Personalized medicine molecular diagnostics firm Myriad Genetics has secured approval from the US Food and Drug Administration (FDA)…